

CERTIFICATE OF PARTICIPATION

Survey of 27 January 2023

You have participated in the External Quality Assessment with the following analysis

Psychotherapeutic Drugs 03 (862):

Clozapine
Olanzapine

(R) analysis is subject to the RiliBÄK

Participant:
42935
MUDr.,PhD. Tomas Salek
Krajska nemocnice T.Bata, a.s.
Department of Clinical Biochemistry &
Pharmacology
Havlickovo nabrezi 600
76275 Zlin

Düsseldorf, 13 February 2023



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dr. rer. nat. Ekkehard Haen
(Adviser)

CERTIFICATE

Survey of 27 January 2023

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Psychotherapeutic Drugs 03 (862):

Validity 12 months:

Clozapine

Olanzapine

(R) analysis is subject to the RiliBÄK

Participant:

42935

MUDr.,PhD. Tomas Salek

Krajska nemocnice T.Bata, a.s.


Department of Clinical Biochemistry &

Pharmacology

Havlickovo nabrezi 600

76275 Zlin

Düsseldorf, 13 February 2023



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dr. rer. nat. Ekkehard Haen
(Adviser)